BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AZN upcoming catalysts

AstraZeneca: 15 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (8 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 59 readout(s) and 18 FDA event(s). Subscribe to AZN (.ics).

Drugs: Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Pemetrexed, AZD6234, Bevacizumab, Lenvatinib, AZD0780, Osimertinib, AZD9550, AZD0901, Gemcitabine, Pembrolizumab, Paclitaxel, Benralizumab, Anifrolumab, Oleclumab, Tezepelumab, Savolitinib, Irinotecan, Capivasertib, Volrustomig, Rilvegostomig, AZD0754, AZD2287, Baxdrostat/dapagliflozin, Monalizumab, Dato-DXd, Trastuzumab deruxtecan, AZD4144, Leucovorin, Fulvestrant, Dapagliflozin, ICS-LABA, Rosuvastatin, Domvanalimab, Olaparib, Etoposide

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-24 est.P1/P2AstraZeneca AZNNCT06267729 Study of AZD0754 in Participants With Metastatic Prostate CancerMetastatic Prostate Cancerrecruiting60
2026-11-30 est.P2AstraZeneca AZNNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting114
2026-12-10 est.P2AstraZeneca AZNNCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic KiChronic Kidney Disease and Hypertensionactive not recruiting222
2026-12-23 est.P3AstraZeneca AZNNCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of BenralizumAsthmaactive not recruiting94
2026-12-31 est.P3AstraZeneca AZNNCT05303532 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabCancerenrolling by invitation214
2027-01-04 est.P3AstraZeneca AZNNCT07000136 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHHeterozygous Familial Hypercholesterolaemiaactive not recruiting473
2027-01-06 est.P3AstraZeneca AZNNCT05925803 Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Systemic Sclerosis; Sclerodermaactive not recruiting314
2027-01-08 est.P3AstraZeneca AZNNCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Non-Small Cell Lung Canceractive not recruiting1051
2027-01-11 est.P3AstraZeneca AZNNCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGMetastatic Non-small Cell Lung Canceractive not recruiting768
2027-01-11 est.P3AstraZeneca AZNNCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventCardiovascular Diseaseactive not recruiting3103
2027-01-13 est.P3AstraZeneca AZNNCT06706817 A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabChronic Rhinosinusitis With Nasal Polypsactive not recruiting181
2027-01-18 est.P2AstraZeneca AZNNCT05374603 Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCLung Canceractive not recruiting47
2027-01-29 est.P1/P2AstraZeneca AZNNCT06151964 A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightOverweight and Obesityactive not recruiting166
2027-02-10 est.P2AstraZeneca AZNNCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)active not recruiting127
2027-02-11 est.P2AstraZeneca AZNNCT07215702 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.Sepsis; Acute Kidney Injuryrecruiting124

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-11-13FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2026-11-13: IMFINZI (BLA761069 SUPPL59)
2026-10-08FDA approvalapprovedASTRAZENECA AB AZNBREZTRI AEROSPHEREApproved 2026-10-08: BREZTRI AEROSPHERE (NDA220290 ORIG1)
2026-09-16FDA approvalapprovedASTRAZENECA AZNTRUQAPApproved 2026-09-16: TRUQAP (NDA218197 SUPPL6)
2026-09-14FDA approvalapprovedASTRAZENECA AZNTAGRISSOApproved 2026-09-14: TAGRISSO (NDA208065 SUPPL35)
2026-09-04FDA approvalapprovedASTRAZENECA AZNETCAMAHApproved 2026-09-04: ETCAMAH (NDA220359 ORIG1)
2026-06-12FDA approvalapprovedASTRAZENECA AZNTRUQAPApproved 2026-06-12: TRUQAP (NDA218197 SUPPL4)
2026-05-28FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2026-05-28: IMFINZI (BLA761069 SUPPL53)
2026-05-15FDA approvalapprovedASTRAZENECA AB AZNBAXFENDYApproved 2026-05-15: BAXFENDY (NDA219878 ORIG1)
2026-05-13FDA approvalapprovedASTRAZENECA AB AZNFASENRAApproved 2026-05-13: FASENRA (BLA761070 SUPPL23)
2026-04-30FDA AdComheldAstraZeneca Pharmaceuticals LP AZNAdCom 2026-04-30: Oncologic Drugs Advisory Committee - NDA 220359, sNDA 218197/S-004
2026-04-27FDA approvalapprovedASTRAZENECA AZNSYMBICORT AEROSPHEREApproved 2026-04-27: SYMBICORT AEROSPHERE (NDA216579 SUPPL1)
2026-04-27FDA approvalapprovedASTRAZENECA AB AZNBREZTRI AEROSPHEREApproved 2026-04-27: BREZTRI AEROSPHERE (NDA212122 SUPPL9)
2026-04-24FDA approvalapprovedASTRAZENECA AB AZNSAPHNELOApproved 2026-04-24: SAPHNELO (BLA761451 ORIG1)
2026-04-15FDA approvalapprovedASTRAZENECA AB AZNWAINUAApproved 2026-04-15: WAINUA; WAINUA (AUTOINJECTOR) (NDA217388 SUPPL5)
2026-02-19FDA approvalapprovedASTRAZENECA AZNCALQUENCEApproved 2026-02-19: CALQUENCE (NDA210259 SUPPL12)
2026-02-19FDA approvalapprovedASTRAZENECA AZNCALQUENCEApproved 2026-02-19: CALQUENCE (NDA216387 SUPPL6)
2025-11-25FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2025-11-25: IMFINZI (BLA761069 SUPPL52)
2025-11-19FDA approvalapprovedASTRAZENECA AZNKOSELUGOApproved 2025-11-19: KOSELUGO (NDA213756 SUPPL6)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11-05 est.P1/P2AstraZeneca AZNNCT07336446 A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsProstate Canceractive not recruiting6
2026-11-02P3AstraZeneca AZNNCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusCutaneous Lupus Erythematosusactive not recruiting339
2026-10-31 est.P3AstraZeneca AZNNCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsBreast Canceractive not recruiting293
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10-23 est.P2AstraZeneca AZNNCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightObesity/Overweightactive not recruiting16
2026-10-01P1/P2AstraZeneca AZNNCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)RSV Respiratory Syncytial Virusactive not recruiting164
2026-09-30 est.P3AstraZeneca AZNNCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCHepatocellular Carcinomaactive not recruiting214
2026-09-26 est.P2AstraZeneca AZNNCT06942910 A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease andChronic Kidney Disease With High Proteinuriaactive not recruiting224
2026-09-21P3AstraZeneca AZNNCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated Eosinophilic Asthmacompleted130
2026-09-03P2AstraZeneca AZNNCT07218900 A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult ParDyslipidaemiacompleted76
2026-08-17P3AstraZeneca AZNNCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Metastatic Non-small Cell Lung Canceractive not recruiting895
2026-08-14P2AstraZeneca AZNNCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.Gastric Cancer; Gastroesophageal Junction Canceractive not recruiting33
2026-08-10P2AstraZeneca AZNNCT06681324 Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyCrohn's Diseaseactive not recruiting24
2026-08-10P3AstraZeneca AZNNCT05267613 Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.Erosive Esophagitiscompleted53
2026-08-10P3AstraZeneca AZNNCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNon-Small Cell Lung Canceractive not recruiting791
2026-07-27 est.P3AstraZeneca AZNNCT04884360 D9319C00001- 1L OC Mono Global RCTOvarian Canceractive not recruiting366
2026-07-14P3AstraZeneca AZNNCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisEosinophilic Esophagitisactive not recruiting368
2026-07-10P3AstraZeneca AZNNCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete TuNon-small Cell Lung Canceractive not recruiting25
2026-07-07P2AstraZeneca AZNNCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsLung Canceractive not recruiting76
2026-07-06P3AstraZeneca AZNNCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatCarcinoma; Non-Small-Cell Lungactive not recruiting341
2026-06-30P2AstraZeneca AZNNCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Hepatocellular Carcinoma (HCC)active not recruiting58
2026-06-30 est.P2AstraZeneca AZNNCT05825365 Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled StudyNeurofibromatosis Type 1; Plexiform Neurofibromas; Post-operativewithdrawn
2026-06-26P3AstraZeneca AZNNCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not ReceivER-Positive HER2-Negative Breast Canceractive not recruiting1371
2026-06-09P3AstraZeneca AZNNCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small CLocally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting454
2026-06-01P3AstraZeneca AZNNCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Canceractive not recruiting1246
2026-05-31P3AstraZeneca AZNNCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdGastric Cancer; Gastroesophageal Junction Canceractive not recruiting594
2026-05-26P2AstraZeneca AZNNCT06851858 Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AEndocrinology; Diabetes, Type II; Obesitycompleted69
2026-05-15P3AstraZeneca AZNNCT03847428 Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentHepatocellular Carcinomacompleted908
2026-05-13P3AstraZeneca AZNNCT06465485 STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaSevere Eosinophilic Asthmacompleted504
2026-05-13P3AstraZeneca AZNNCT06194825 EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardTransthyretin Amyloid Cardiomyopathyactive not recruiting64
2026-05-11P2AstraZeneca AZNNCT06862791 A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneObesity or Overweightcompleted377
2026-05-04P2AstraZeneca AZNNCT06606847 A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Non-Small Cell Lung Canceractive not recruiting30
2026-04-30P2AstraZeneca AZNNCT06450197 Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseModerate to Severe Crohn's Diseaseactive not recruiting120
2026-04-21P2AstraZeneca AZNNCT06897748 A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Chronic Obstructive Pulmonary Disease (COPD)completed98
2026-04-17P3AstraZeneca AZNNCT06502366 A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Asthmacompleted424
2026-03-30P3AstraZeneca AZNNCT05883644 Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Advanced Hepatocellular Carcinomaactive not recruiting111
2026-03-16 est.P3AstraZeneca AZNNCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCTriple Negative Breast Neoplasmsactive not recruiting923
2026-03-06P3AstraZeneca AZNNCT06040086 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsChronic Obstructive Pulmonary Disease (COPD)completed1454
2026-03-04 est.P3AstraZeneca AZNNCT05348577 Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Prostate Canceractive not recruiting1035
2026-03-02P3AstraZeneca AZNNCT04960709 Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer InMuscle Invasive Bladder Canceractive not recruiting712
2026-02-26P3AstraZeneca AZNNCT05742802 Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).Chronic Obstructive Pulmonary Disease (COPD)completed1713
2026-02-23P3AstraZeneca AZNNCT05301842 Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCHepatocellular Carcinomaactive not recruiting760
2026-02-10P2AstraZeneca AZNNCT06299826 A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailureChronic Heart Failurecompleted375
2026-02-04P2AstraZeneca AZNNCT06529419 A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsAsthmacompleted537
2026-01-28P1/P2AstraZeneca AZNNCT07128615 A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Influenza Aactive not recruiting405
2026-01-22P3AstraZeneca AZNNCT06067828 A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDIChronic Obstructive Pulmonary Diseasecompleted171
2026-01-19P3AstraZeneca AZNNCT05166889 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsChronic Obstructive Pulmonary Disease (COPD)completed1132
2026-01-19P3AstraZeneca AZNNCT05158387 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.Chronic Obstructive Pulmonary Disease (COPD)completed1172
2026-01-12P2AstraZeneca AZNNCT05925530 Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in ResectNon-small Cell Lung Canceractive not recruiting142
2026-01-07P2AstraZeneca AZNNCT05251259 Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaAsthmacompleted670
2025-12-31P3AstraZeneca AZNNCT05043090 Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCPapillary Renal Cell Carcinomaactive not recruiting148
2025-12-19 est.P1/P2AstraZeneca AZNNCT07060365 A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Advanced/Recurrent Ovarian Cancerwithdrawn
2025-12-19P2AstraZeneca AZNNCT06579105 Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2completed406
2025-12-03P2AstraZeneca AZNNCT06595238 A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityObesity or Overweightcompleted262
2025-11-24P3AstraZeneca AZNNCT06344104 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants WiUncontrolled Hypertension; Resistant Hypertensioncompleted326
2025-11-24P3AstraZeneca AZNNCT05110261 Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in ChinaLower Respiratory Tract Infectioncompleted800
2025-11-21P2AstraZeneca AZNNCT06579092 Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityObesity or Overweightcompleted310

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.